{"entity":{"id":"nct05893888","kind":"trial","name":"A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subjects With Oral and Lung Cancers","aka":[],"tldr":"A phase 2/3 trial of Cisplatin in head and neck squamous cell carcinoma, run by Privo Technologies, now recruiting.","summary":"A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subjects With Oral and Lung Cancers is a phase 2/3 interventional study registered as NCT05893888 by Privo Technologies, with 40 participants planned, started 2024-11-07 and due to reach its primary completion in 2026-10. Interventions recorded: PRV211 (Intraoperative Cisplatin System), PRV111 (Cisplatin Transmucosal System) and PRV131 (Cisplatin Intratumoral Injectable).","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05893888","url":"https://clinicaltrials.gov/study/NCT05893888"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["head-and-neck"],"sections":[],"technologies":[],"targets":[],"drugs":["cisplatin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05893888","phase":"2/3","setting":"A Phase 1/2/3 Multicenter Study Evaluating the PRV Platform of Localized Nanoengineered Therapies for Oral Cavity and Lung Cancers","sponsor":"Privo Technologies","enrolled":40,"outcomes":[]},"route":"/trials/nct05893888/","neighbours":{"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"}],"drug":[{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"}]}}